search
Back to results

Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity

Primary Purpose

Morbid Obesity

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Intragastric Balloon (IGB), group A
diet, control group B
Sponsored by
Hospital Severo Ochoa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Morbid Obesity focused on measuring morbid obesity, bioenterics intragastric balloon, bariatric surgery

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. - Morbid obesity (BMI ≥ 40 kg/m2 ) with a failed Conventional Medical treatment
  2. - Morbid obesity (BMI ≥ 35 kg/m2) with important comorbidity with a failed Conventional Medical treatment
  3. - they should be operated by a laparoscopic gastric sleeve or by laparoscopic gastric by-pass

Exclusion Criteria:

  1. - Slight adherence to previous medical treatments .
  2. - Hiatal hernia more than 3 cms
  3. - Patients with active gastric or duodenal ulcer disease
  4. - Severe esophagitis
  5. - Psychiatric diseases (depression, bulimia etc)
  6. - Associated Severe Systemic Disease not amenable to improve with weight loss
  7. - Patients with Inflammatory bowel diseases
  8. - Patients on anticoagulant treatment or steroids .
  9. - Addiction to Drugs or alcohol
  10. - Past history of gastric surgery ,antireflux surgery or any other type of bariatric surgery
  11. - Patient refusing to be followed 6 months before and after surgery
  12. - Pregnancy or foreseeable pregnancy during the study
  13. - Patients with gastric or esophageal varices
  14. - proton pump inhibitor (PPI) allergy

Sites / Locations

  • Gastroenterology Department ,Severo Ochoa Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

IGB group A

control group B

Arm Description

the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)

the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)

Outcomes

Primary Outcome Measures

Postsurgical Morbidity on Both Arms of the Study
postsurgical morbidity includes all kind of post operative morbidity( mild ,moderate and severe) moderate and severe post surgical morbidity is the most important one
Total Postsurgical Morbidity
total postsurgical morbidity included the morbidity specifically due to the Intragastric balloon plus all the postoperative morbidity related to the surgical procedure severe intragastric balloon morbidity refers only to medical complications which meet the criteria of severe of "The accordion severity grading system ".

Secondary Outcome Measures

Hospital Stay,
all in all hospital stay
Rate of Surgical Conversion to Open Surgery
number of patients with surgical conversion from laparoscopic to open surgery
Percentage of Re-operations
Percentage of Re-operations during all the period of the study ending within 90 days after surgery

Full Information

First Posted
November 19, 2013
Last Updated
March 11, 2019
Sponsor
Hospital Severo Ochoa
Collaborators
Instituto de Salud Carlos III
search

1. Study Identification

Unique Protocol Identification Number
NCT01998243
Brief Title
Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity
Official Title
Usefulness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity To Decrease Bariatric Surgery Morbidity
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
January 2009 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Severo Ochoa
Collaborators
Instituto de Salud Carlos III

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Introduction: bariatric surgery shows an important morbidity and there are some reports that have used preoperative intragastric-balloons (IGB-BIB®) to decrease surgical morbidity. Patients Methods: Since 2009 we are performing a randomized and prospective study to assess the usefulness of (IGB-BIB®) before bariatric surgery [sleeve resection (SR) or gastric bypass (GB)] "group A". The intervention in this group was was to place an intragastric Balloon for 6 months vs a control group "B" with the same type of surgical procedures but without preoperative IGB-BIB.The intervention on this group was only to treat the obesity only with diet for 6 months . All patients coming for both groups were followed at 4-week intervals by a nurse practitioner and dietitian for 6 months, Nurse practitioner made the dietetics adjustments (750-1500 Kcal) , provide advice and assess the evolution of weight loss The hypothesis was that preoperative IGB-BIB helps the patients to lose weight ( more than 10%) ,and the weight loss will contribute to decrease surgical morbidity by at least 30%, and also will decrease hospital stay Objective: to check if morbidity, mortality and hospital stay decreased in the IGB-BIB ® group, and secondly if the weight before surgery was associated with surgical morbidity. secondary objective : Assess the rate of IGB-BIB failure.Intragastric balloon failure was considered when the weight loss is less than 10% from the initial weight. We defined severe complication whenever the patient had to be admitted in the hospital after discharge, new surgeries or transfusions were required or the hospital stay was longer than 7-10 days.
Detailed Description
Treatment with an intragastric balloon (IGB) for morbid obesity is a temporary treatment reached as a second step, when the initial nutritional multidisciplinary approach has failed; however, its value is not clear compared with other conventional medical treatments ], though some authors have stated that IGB achieves higher weight loss than conventional diet treatments (12.2% of the initial weight) ]; and others have positioned IGB as the first valid step in order to achieve weight loss in patients who are adequate for a future gastric bypass surgery. Genco et al (2009) have compared the treatment with IGB only vs. laparoscopic sleeve gastrectomy (LSG), and have found no differences in the amount of weight loss at 6 months, but a reduction in adverse events caused by IGB treatment. One of the potential future indications for the intragastric balloon could be its use as a bridge-treatment until bariatric surgery, not only in order to achieve weight loss before surgery, but also to select the group of patients who might benefit more from derivative surgery, as suggested by some authors or its use in special populations such as super-obese patients . The objective would be to reduce weight before the surgical procedure, in order to improve comorbidities, facilitate the surgical technique, and potentially reduce any surgical complications. It is increasingly frequent in many surgical units to try and achieve weigh loss before bariatric surgery, using intragastric balloons (IGB). However, this therapeutic approach currently presents dubious utility. Our study intends to contribute with our experience in the evaluation of IGB before surgery for achieving weight loss, and its impact on post-surgical morbidity. Bariatric surgery shows an important morbidity and there are not to many randomized prospective studies using intragastric- balloons (IGB-BIB®) to evaluate if getting weight lost really matter on decreasing surgical complications before Bariatric surgery OBJECTIVE: To study the usefulness of preoperative IGB-BIB® "grA" [sleeve resection (SR) or gastric bypass (GB)] to help decrease postsurgical complications. Secondly we try to check the rate of IGB-BIB® failures (a total weight loss less than 10% of the initial weight), and the impact on decreasing hospital stay and rate of surgical reoperations. METHODS: The study was a clinical prospective and randomized essay coming from 2009. Cases (grA) had an IGB during 6 months before surgery vs Controls (grB)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
Keywords
morbid obesity, bioenterics intragastric balloon, bariatric surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
81 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IGB group A
Arm Type
Experimental
Arm Description
the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
Arm Title
control group B
Arm Type
Placebo Comparator
Arm Description
the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
Intervention Type
Device
Intervention Name(s)
Intragastric Balloon (IGB), group A
Other Intervention Name(s)
BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM
Intervention Description
the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
Intervention Type
Other
Intervention Name(s)
diet, control group B
Other Intervention Name(s)
1200 Kilocalories (Kcal) diet
Intervention Description
the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
Primary Outcome Measure Information:
Title
Postsurgical Morbidity on Both Arms of the Study
Description
postsurgical morbidity includes all kind of post operative morbidity( mild ,moderate and severe) moderate and severe post surgical morbidity is the most important one
Time Frame
within the 90 days after surgery
Title
Total Postsurgical Morbidity
Description
total postsurgical morbidity included the morbidity specifically due to the Intragastric balloon plus all the postoperative morbidity related to the surgical procedure severe intragastric balloon morbidity refers only to medical complications which meet the criteria of severe of "The accordion severity grading system ".
Time Frame
during the 6 months having the intragastric balloon and 90 days after surgery
Secondary Outcome Measure Information:
Title
Hospital Stay,
Description
all in all hospital stay
Time Frame
the period of the study started when patients were randomizated and finished 90 days after surgery
Title
Rate of Surgical Conversion to Open Surgery
Description
number of patients with surgical conversion from laparoscopic to open surgery
Time Frame
during the initial laparoscopic surgery
Title
Percentage of Re-operations
Description
Percentage of Re-operations during all the period of the study ending within 90 days after surgery
Time Frame
during all the period of the study ending within 90 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Morbid obesity (BMI ≥ 40 kg/m2 ) with a failed Conventional Medical treatment - Morbid obesity (BMI ≥ 35 kg/m2) with important comorbidity with a failed Conventional Medical treatment - they should be operated by a laparoscopic gastric sleeve or by laparoscopic gastric by-pass Exclusion Criteria: - Slight adherence to previous medical treatments . - Hiatal hernia more than 3 cms - Patients with active gastric or duodenal ulcer disease - Severe esophagitis - Psychiatric diseases (depression, bulimia etc) - Associated Severe Systemic Disease not amenable to improve with weight loss - Patients with Inflammatory bowel diseases - Patients on anticoagulant treatment or steroids . - Addiction to Drugs or alcohol - Past history of gastric surgery ,antireflux surgery or any other type of bariatric surgery - Patient refusing to be followed 6 months before and after surgery - Pregnancy or foreseeable pregnancy during the study - Patients with gastric or esophageal varices - proton pump inhibitor (PPI) allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luis R Rábago, MD,PhD
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gastroenterology Department ,Severo Ochoa Hospital
City
Leganés
State/Province
Madrid
ZIP/Postal Code
28911
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
11433910
Citation
Hodson RM, Zacharoulis D, Goutzamani E, Slee P, Wood S, Wedgwood KR. Management of obesity with the new intragastric balloon. Obes Surg. 2001 Jun;11(3):327-9. doi: 10.1381/096089201321336692.
Results Reference
background
PubMed Identifier
11433911
Citation
Loffredo A, Cappuccio M, De Luca M, de Werra C, Galloro G, Naddeo M, Forestieri P. Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001 Jun;11(3):330-3. doi: 10.1381/096089201321336700.
Results Reference
background
PubMed Identifier
12194556
Citation
Doldi SB, Micheletto G, Perrini MN, Librenti MC, Rella S. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002 Aug;12(4):583-7. doi: 10.1381/096089202762252398.
Results Reference
background
PubMed Identifier
15186637
Citation
Busetto L, Segato G, De Luca M, Bortolozzi E, MacCari T, Magon A, Inelmen EM, Favretti F, Enzi G. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg. 2004 May;14(5):671-6. doi: 10.1381/096089204323093471.
Results Reference
background
PubMed Identifier
15329191
Citation
Sallet JA, Marchesini JB, Paiva DS, Komoto K, Pizani CE, Ribeiro ML, Miguel P, Ferraz AM, Sallet PC. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004 Aug;14(7):991-8. doi: 10.1381/0960892041719671.
Results Reference
background
PubMed Identifier
16469215
Citation
Alfalah H, Philippe B, Ghazal F, Jany T, Arnalsteen L, Romon M, Pattou F. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg. 2006 Feb;16(2):147-50. doi: 10.1381/096089206775565104.
Results Reference
background
PubMed Identifier
31399943
Citation
Vicente Martin C, Rabago Torre LR, Castillo Herrera LA, Arias Rivero M, Perez Ferrer M, Collado Pacheco D, Martin Rios MD, Barba Martin R, Ramiro Martin J, Vazquez-Echarri J, Herrera Merino N. Preoperative intragastric balloon in morbid obesity is unable to decrease early postoperative morbidity of bariatric surgery (sleeve gastrectomy and gastric bypass): a clinical assay. Surg Endosc. 2020 Jun;34(6):2519-2531. doi: 10.1007/s00464-019-07061-w. Epub 2019 Aug 9.
Results Reference
derived

Learn more about this trial

Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity

We'll reach out to this number within 24 hrs